Brief: Evaxion Biotech A/S Positive Clinical Response As Demonstrated In 8 Out Of 12 Patients Receiving Evx-01 In Combination With A Checkpoint Inhibitor

Evaxion A/S

25/05/2023 23:19

Evaxion Biotech A/S  EVAX.O :
    * EVAXION BIOTECH A/S: POSITIVE CLINICAL RESPONSE AS
DEMONSTRATED
IN 8 OUT OF 12 PATIENTS RECEIVING EVX-01 IN COMBINATION WITH A
CHECKPOINT INHIBITOR
    * EVAXION BIOTECH A/S: STUDY MET PRIMARY ENDPOINTS FOR
TOLERABILITY AND SAFETY
    * EVAXION BIOTECH A/S: BROAD NEOANTIGEN T-CELL RESPONSES
WERE
INDUCED IN ALL 12 PATIENTS
    * EVAXION BIOTECH A/S: 58% OF VACCINE NEOANTIGENS INDUCED AN
IMMUNE RESPONSE, OF WHICH 85% WERE DE NOVO RESPONSES
    * EVAXION BIOTECH A/S: EIGHT OUT OF TWELVE PATIENTS HAD AN
OBJECTIVE RESPONSE, INCLUDING TWO COMPLETE RESPONDERS AND SIX
PARTIAL RESPONDERS
    * EVAXION BIOTECH A/S: EXPECT TO REPORT INTERIM RESULTS FROM
OUR
ONGOING PHASE 2 STUDY OF EVX-01 IN Q4 2023

Source text for Eikon:  ID:nGNX2NShQN 
Further company coverage:  EVAX.O